Italia markets closed
Dow Jones
38.839,63 +163,95 (+0,42%) Nasdaq
16.299,76 +143,44 (+0,89%) Nikkei 225
38.236,07 -38,03 (-0,10%) EUR/USD
1,0777 +0,0010 (+0,10%) Bitcoin EUR
58.634,00 -849,43 (-1,43%) CMC Crypto 200
1.361,60 +48,98 (+3,73%)
Neurocrine Biosciences, Inc. (NBIX)
NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
In data: 02:24PM EDT. Mercato aperto.
| Chiusura precedente | 140,71 |
| Aperto | 140,55 |
| Denaro | 142,19 x 100 |
| Lettera | 154,60 x 200 |
| Min-Max giorno | 140,55 - 143,57 |
| Intervallo di 52 settimane | 89,04 - 148,37 |
| Volume | |
| Media Volume | 909.878 |
| Capitalizzazione | 14,313B |
| Beta (5 anni mensile) | 0,28 |
| Rapporto PE (ttm) | 38,54 |
| EPS (ttm) | 3,69 |
| Prossima data utili | 30 lug 2024 - 05 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | 29 dic 1995 |
| Stima target 1A | 157,92 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.